Evaluation of multiparametric flow cytometry in diagnosis & prognosis of myelodysplastic syndrome in India
Authors:
Open Access
- 1 September 2020
- journal article
- research article
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 152 (3) , 254-262
Abstract
Background & objectives: Diagnosis of myelodysplastic syndromes (MDS) is subjective in low-grade cases with Methods: This study included 44 consecutive clinically suspected cases of MDS with refractory cytopenia(s) and 10 controls. Patients were divided into two groups: (i) proven MDS cases (n=26), and (ii) suspected MDS (n=18). Ogata quantitative approach, pattern analysis and aberrant antigen expression were studied. Results: Ogata score ≥2 correctly diagnosed 80.7 per cent (21/26) while aberrant antigen and pattern analysis with flow score of ≥3 could diagnose 92.3 per cent (24/26) patients with proven MDS. Combination of both with flow score ≥3 could diagnose 100 per cent patients. Eight patients in suspected MDS group with persistent cytopenia on follow up were labelled as probable MDS. Ogata score ≥2 was present in 5 of 8 and pattern analysis score ≥3 was present in six probable MDS patients. Combination of both with flow score ≥3 was present in seven of eight patients. Spearman's correlation between Ogata score and R-IPSS, pattern analysis and R-IPSS and combination of both scores and R-IPSS showed significant positive correlation in proven MDS as well as when proven and probable MDS patients were combined. Interpretation & conclusions: Our results showed that combined Ogata approach and pattern analysis, demonstration of ≥3 aberrancies in >1 cell compartment could diagnose most MDS patients. Patients with high flow scores had high R-IPSS scores. Patient with flow score ≥3 and borderline cytomorphology should be observed closely for the development of MDS.Keywords
This publication has 27 references indexed in Scilit:
- Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working GroupLeukemia & Lymphoma, 2012
- Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular geneticsHaematologica, 2012
- Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET studyHaematologica, 2012
- Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research NetworkBritish Journal of Cancer, 2011
- Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndromeCancer, 2010
- Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation studyHaematologica, 2009
- Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromesHaematologica, 2009
- An analysis of 30 cases of myelodysplastic syndromeIndian Journal of Pathology and Microbiology, 2009
- Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician SurveysJNCI: Journal of the National Cancer Institute, 2008
- Diagnostic flow cytometry for low‐grade myelodysplastic syndromesHematological Oncology, 2008